Rett syndrome (RTT) is a progressive neurodevelopmental disorder caused by variants in MECP2. Emerging evidence of ethnic specificity of genetic variations has allowed precise diagnostic approaches with tailored therapies. In this study, we reviewed the variation spectrum of MECP2 in Korean RTT(-like) patients and compared it with previous reports in multiple ethnic groups. We reevaluated variants found in Korean RTT patients according to the new Clinical Genome Resource guideline to reinterpret and reclassify variants of uncertain significance in MECP2. Among 377 cases, 56 (14.9%) showed pathogenic variants, and three novel variants, p.(Ala277Argfs*7), p.(Ala378Glyfs*8), and p.(Arg270_Ser332del), were identified. Comprehensive data from Korea revealed an overall consistent variation spectrum with those from other ethnicities. Through the reevaluation of variants, nine that previously had insufficient evidence for pathogenicity were reclassified into pathogenic variants. Our study provided insight on the genetic contribution of MECP2 in RTT and a useful background for genetic counseling in the Korean population.
Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185–8.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
ClinGen Rett and Angelman-like Disorders Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1. https://clinicalgenome.org/docs/clingen-rett-and-angelman-like-disorders-expert-panel-specifications-to-the-acmg-amp-variant-interpretation-guidelines-version-1/ (Updated on Feb 2021).
Bhaskaran SP, Chandratre K, Gupta H, Zhang L, Wang X, Cui J, et al. Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients. Int J Cancer. 2019;145:962–73.
Kim HJ, Kim SH, Kim HD, Lee JS, Lee YM, Koo KY, et al. Genetic and epileptic features in Rett syndrome. Yonsei Med J. 2012;53:495–500.
Kim IJ, Kim YJ, Son BH, Nam SO, Kang HC, Kim HD, et al. Diagnostic mutational analysis of MECP2 in Korean patients with Rett syndrome. Exp Mol Med. 2006;38:119–25.
Chae JH, Hwang H, Hwang YS, Cheong HJ, Kim KJ. Influence of MECP2 gene mutation and X-chromosome inactivation on the Rett syndrome phenotype. J Child Neurol. 2004;19:503–8.
Good KV, Vincent JB, Ausió J. MeCP2: The Genetic Driver of Rett Syndrome Epigenetics. Front Genet. 2021;12:620859.
Fukuda T, Yamashita Y, Nagamitsu S, Miyamoto K, Jin JJ, Ohmori I, et al. Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: pathological mutations and polymorphisms. Brain Dev. 2005;27:211–7.
Li MR, Pan H, Bao XH, Zhang YZ, Wu XR. MECP2 and CDKL5 gene mutation analysis in Chinese patients with Rett syndrome. J Hum Genet. 2007;52:38–47.
Khajuria R, Gupta N, van Roozendaal KEP, Sapra S, Ghosh M, Gulati S, et al. Spectrum of MECP2 mutations in Indian females with Rett Syndrome—a large cohort study. J Transl Genet Genomics. 2020;4:91–103.
Percy AK, Lane JB, Childers J, Skinner S, Annese F, Barrish J, et al. Rett syndrome: North American database. J Child Neurol. 2007;22:1338–41.
Krishnaraj R, Ho G, Christodoulou J. RettBASE: Rett syndrome database update. Hum Mutat. 2017;38:922–31.
Wen Y, Wang J, Zhang Q, Chen Y, Wu X, Bao X. MECP2 mutation spectrum and its clinical characteristics in a Chinese cohort. Clin Genet. 2020;98:240–50.
Philippe C, Villard L, De Roux N, Raynaud M, Bonnefond JP, Pasquier L, et al. Spectrum and distribution of MECP2 mutations in 424 Rett syndrome patients: a molecular update. Eur J Med Genet. 2006;49:9–18.
Le Thi Thanh H, Do Thi Diem T, Duy CV, Thanh HLT, Phuong HBT, Thanh LN. Spectrum of MECP2 mutations in Vietnamese patients with RETT syndrome. BMC Med Genet. 2018;19:137.
Vacca M, Filippini F, Budillon A, Rossi V, Della Ragione F, De, et al. MECP2 gene mutation analysis in the British and Italian Rett Syndrome patients: hot spot map of the most recurrent mutations and bioinformatic analysis of a new MECP2 conserved region. Brain Dev. 2001;23 Suppl 1:S246–50.
Laccone F, Huppke P, Hanefeld F, Meins M. Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions. Hum Mutat. 2001;17:183–90.
Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat. 2018;39:1517–24.
Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Schanen C, et al. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J Med Genet. 2003;40:487–93.
Brown K, Selfridge J, Lagger S, Connelly J, De Sousa D, Kerr A, et al. The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum Mol Genet. 2016;25:558–70.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kim, J.A., Kwon, W.K., Kim, JW. et al. Variation spectrum of MECP2 in Korean patients with Rett and Rett-like syndrome: a literature review and reevaluation of variants based on the ClinGen guideline. J Hum Genet (2022). https://doi.org/10.1038/s10038-022-01044-x